BioCryst Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BCRX Nasdaq 2836 www.biocryst.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioCryst Pharmaceuticals, Inc.

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Feb 11th, 2026 5:00 am
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Feb 7th, 2026 2:04 pm
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” - Feb 6th, 2026 10:56 pm
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - Feb 5th, 2026 5:01 am
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 5th, 2026 5:00 am
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? - Jan 30th, 2026 5:35 am
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus - Jan 24th, 2026 2:12 pm
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Jan 23rd, 2026 7:00 am
Astria Stockholders Vote to Approve Acquisition by BioCryst - Jan 21st, 2026 2:00 pm
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - Jan 13th, 2026 12:04 am
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - Jan 12th, 2026 5:00 am
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Jan 8th, 2026 7:12 am
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 5:00 am
BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says - Dec 30th, 2025 5:22 am
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Dec 21st, 2025 7:57 am
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Dec 15th, 2025 6:06 pm
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks - Dec 14th, 2025 4:05 am
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday as Broadcom Results Deepen Fears - Dec 12th, 2025 6:55 am
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years - Dec 12th, 2025 5:00 am
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - Dec 4th, 2025 11:09 am